Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide

BACKGROUND: Acute promyelocytic leukemia (APL) is a model for synergistic target cancer therapy using all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), which yields a very high 5-year overall survival (OS) rate of 85 to 90%. Nevertheless, about 15% of APL patients still get early death or r...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Yang, Fu, Ya-Kai, Zhu, Yong-Mei, Lou, Yin-Jun, Gu, Zhao-Hui, Shi, Jing-Yi, Chen, Bing, Chen, Chao, Zhu, Hong-Hu, Hu, Jiong, Zhao, Wei-Li, Mi, Jian-Qing, Chen, Li, Zhu, Hong-Ming, Shen, Zhi-Xiang, Jin, Jie, Wang, Zhen-Yi, Li, Jun-Min, Chen, Zhu, Chen, Sai-Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535155/
https://www.ncbi.nlm.nih.gov/pubmed/26285909
http://dx.doi.org/10.1016/j.ebiom.2015.04.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535155/
https://www.ncbi.nlm.nih.gov/pubmed/26285909
http://dx.doi.org/10.1016/j.ebiom.2015.04.006

Ejemplares similares